{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T01:37:36Z","timestamp":1794101856076,"version":"4.8.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hemophilia B is a rare bleeding disorder in males, characterized by a deficiency in coagulation factor IX (FIX). Replacement of FIX with a recombinant FIX (rFIX) fusion protein, to sustain therapeutic plasma levels, is recommended as both treatment and prophylaxis to prevent bleeding episodes, particularly intracranial hemorrhage (ICH).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>This case report outlines the management of ICH in a 7-month-old infant with severe hemophilia B, following an accidental trauma-related event, resulting in a thin compound fracture of the left occiput. FIX levels were extremely low (\u02c21.0%) and large deletions of the coagulation <jats:italic>F9<\/jats:italic> gene (including exons 1\u20136) were identified. Intensive treatment with a rFIX fusion protein conjugated to the immunoglobulin Fc fragment (rFIXFc) continued for 18 days before hospital discharge. A continuous regimen of weekly rFIXFc infusions was implemented. Thirty days after initiating rFIXFc therapy, neutralizing antibodies or FIX inhibitors (common in patients with large <jats:italic>F9<\/jats:italic> gene deletions) were observed, causing a diffuse skin rash. Such allergic reactions typically indicate progression to potentially serious nephrotic syndrome. A unique immunotolerance regimen of oral oxatomide and intravenous hydrocortisone was started to proactively prevent allergic reactions in this patient during rFIXFc prophylaxis. Even though low titers of the inhibitor (0.6\u20131.0 Bethesda units) were observed occasionally during subsequent follow-up, there were no signs of further allergies or development of nephrotic syndrome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This is an uncommon case in which rFIXFc was continued despite the appearance of an allergic reaction and the development of FIX inhibitors. Subsequent allergic reactions were prevented with a combination of oral oxatomide and intravenous hydrocortisone given prior to prophylactic rFIXFc. Further studies are recommended to determine the usefulness of this combination with rFIX therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13052-024-01819-2","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T11:06:36Z","timestamp":1732791996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intracranial hemorrhage in an infant leads to the diagnosis and treatment of severe hemophilia B: a case report"],"prefix":"10.1186","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7858-1632","authenticated-orcid":false,"given":"Giuseppe","family":"Lassandro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Palladino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"1819_CR1","doi-asserted-by":"publisher","first-page":"540","DOI":"10.7326\/M19-1208","volume":"171","author":"A Iorio","year":"2019","unstructured":"Iorio A, Stonebraker JS, Chambost H, Makris M, Coffin D, Herr C, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171:540\u201346. https:\/\/doi.org\/10.7326\/M19-1208.","journal-title":"Ann Intern Med"},{"key":"1819_CR2","doi-asserted-by":"publisher","unstructured":"Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26 Suppl 6:1-158. https:\/\/doi.org\/10.1111\/hae.14046","DOI":"10.1111\/hae.14046"},{"key":"1819_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/2040620718796429","volume":"9","author":"T Lambert","year":"2018","unstructured":"Lambert T, Benson G, Dolan G, Hermans C, Jim\u00e9nez-Yuste V, Ljung R, et al. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol. 2018;9:295\u2013308. https:\/\/doi.org\/10.1177\/2040620718796429.","journal-title":"Ther Adv Hematol"},{"key":"1819_CR4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s40265-023-01868-7","volume":"83","author":"YN Lamb","year":"2023","unstructured":"Lamb YN, Hoy SM. Eftrenonacog alfa: a review in haemophilia B. Drugs. 2023;83:807\u201318. https:\/\/doi.org\/10.1007\/s40265-023-01868-7.","journal-title":"Drugs"},{"key":"1819_CR5","doi-asserted-by":"publisher","unstructured":"Lyseng-Williamson KA, Coagulation Factor IX (Recombinant), editors. Albumin Fusion Protein (Albutrepenonacog Alfa; Idelvion\u00ae): A Review of Its Use in Haemophilia B. Drugs. 2017;77:97\u2013106. https:\/\/doi.org\/10.1007\/s40265-016-0679-8","DOI":"10.1007\/s40265-016-0679-8"},{"key":"1819_CR6","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/s2352-3026(16)30193-4","volume":"4","author":"K Fischer","year":"2017","unstructured":"Fischer K, Kulkarni R, Nolan B, Mahlangu J, Rangarajan S, Gambino G, et al. Recombinant factor IX fc fusion protein in children with haemophilia B (kids B-LONG): results from a multicentre, non-randomised phase 3 study. Lancet Haematol. 2017;4:e75\u201382. https:\/\/doi.org\/10.1016\/s2352-3026(16)30193-4.","journal-title":"Lancet Haematol"},{"key":"1819_CR7","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/ejh.14168","volume":"112","author":"P Giordano","year":"2024","unstructured":"Giordano P, Pollio B, Sottilotta G, Biasoli C, Daniele F, De Cristofaro R, et al. Pattern of use and clinical outcomes with rIX-FP in pediatric\/adolescent patients with haemophilia B in Italy: results from IDEAL real-world study. Eur J Haematol. 2024;112:765\u201375. https:\/\/doi.org\/10.1111\/ejh.14168.","journal-title":"Eur J Haematol"},{"key":"1819_CR8","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1160\/th16-03-0179","volume":"116","author":"G Kenet","year":"2016","unstructured":"Kenet G, Chambost H, Male C, Lambert T, Halimeh S, Chernova T, et al. Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial. Thromb Haemost. 2016;116:659\u201368. https:\/\/doi.org\/10.1160\/th16-03-0179.","journal-title":"Thromb Haemost"},{"key":"1819_CR9","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1055\/s-0044-1781466","volume":"8","author":"R Lemons","year":"2024","unstructured":"Lemons R, Wang M, Curtin J, Lepatan LM, Male C, Peyvandi F, et al. Safety and efficacy of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in previously untreated patients with hemophilia B. TH Open. 2024;8:e155\u201363. https:\/\/doi.org\/10.1055\/s-0044-1781466.","journal-title":"TH Open"},{"key":"1819_CR10","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1182\/bloodadvances.2020004085","volume":"5","author":"B Nolan","year":"2021","unstructured":"Nolan B, Klukowska A, Shapiro A, Rauch A, Recht M, Ragni M, et al. Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B. Blood Adv. 2021;5:2732\u201339. https:\/\/doi.org\/10.1182\/bloodadvances.2020004085.","journal-title":"Blood Adv"},{"key":"1819_CR11","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3109\/08880018.2014.930768","volume":"31","author":"P Giordano","year":"2014","unstructured":"Giordano P, Lassandro G, Valente M, Molinari AC, Ieran\u00f2 P, Coppola A. Current management of the hemophilic child: a demanding interlocutor. Quality of life and adequate cost-efficacy analysis. Pediatr Hemat Oncol. 2014;31:687\u2013702. https:\/\/doi.org\/10.3109\/08880018.2014.930768.","journal-title":"Pediatr Hemat Oncol"},{"key":"1819_CR12","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1182\/blood-2014-05-577643","volume":"124","author":"CL Kempton","year":"2014","unstructured":"Kempton CL, Meeks SL. Toward optimal therapy for inhibitors in hemophilia. Blood. 2014;124:3365\u201372. https:\/\/doi.org\/10.1182\/blood-2014-05-577643.","journal-title":"Blood"},{"key":"1819_CR13","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3390\/jcm11071969","volume":"11","author":"E Zanon","year":"2022","unstructured":"Zanon E, Pasca S, Demartis F, Tagliaferri A, Santoro C, Cantori I, et al. Intracranial haemorrhage in haemophilia patients is still an open issue: the final results of the Italian EMO.REC Registry. J Clin Med. 2022;11:1969. https:\/\/doi.org\/10.3390\/jcm11071969.","journal-title":"J Clin Med"},{"key":"1819_CR14","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/j.1365-2516.2009.02074.x","volume":"15","author":"R Kulkarni","year":"2009","unstructured":"Kulkarni R, Soucie JM, Lusher J, Presley R, Shapiro A, Gill J, et al. Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from the Centers for Disease Control and Prevention\u2019s (CDC) Universal Data Collection (UDC) project. Haemophilia. 2009;15:1281\u201390. https:\/\/doi.org\/10.1111\/j.1365-2516.2009.02074.x.","journal-title":"Haemophilia"},{"key":"1819_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1055\/s-0041-1740566","volume":"48","author":"A Dorgalaleh","year":"2022","unstructured":"Dorgalaleh A, Farshi Y, Haeri K, Ghanbari OB, Ahmadi A. Risk and management of intracerebral hemorrhage in patients with bleeding disorders. Semin Thromb Hemost. 2022;48:344\u201355. https:\/\/doi.org\/10.1055\/s-0041-1740566.","journal-title":"Semin Thromb Hemost"},{"key":"1819_CR16","volume-title":"Prothrombin time","author":"R Yang","year":"2022","unstructured":"Yang R, Moosavi L. Prothrombin time. StatPearls: Treasure Island (FL); 2022."},{"key":"1819_CR17","doi-asserted-by":"publisher","first-page":"11219","DOI":"10.3390\/ijms231911219","volume":"23","author":"P Billoir","year":"2022","unstructured":"Billoir P, Elie T, Levy JH, Besnier E, Dureuil B, Veber B, et al. Anticoagulation monitoring with activated partial thromboplastin time and anti-xa activity in intensive care unit patients: interest of thrombin generation assay. Int J Molec Sci. 2022;23:11219. https:\/\/doi.org\/10.3390\/ijms231911219.","journal-title":"Int J Molec Sci"},{"key":"1819_CR18","first-page":"1462","volume":"81","author":"J Janus","year":"2010","unstructured":"Janus J, Moerschel SK. Evaluation of anemia in children. Am Fam Physician. 2010;81:1462\u201371.","journal-title":"Am Fam Physician"},{"key":"1819_CR19","unstructured":"Miller CH. Chapter 130 - Mixing studies. In: Shaz BH, Hillyer CD, Reyes Gil M, editors. Transfusion Medicine and Hemostasis (Third Edition). Elsevier; 2019. pp. 783\u2009\u2013\u200984."},{"key":"1819_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.thromres.2022.06.015","volume":"217","author":"K Kihlberg","year":"2022","unstructured":"Kihlberg K, Baghaei F, Bruzelius M, Funding E, Holme PA, Lassila R, et al. Factor IX antibodies and tolerance in hemophilia B in the nordic countries - the impact of F9 variants and complications. Thromb Res. 2022;217:22\u201332. https:\/\/doi.org\/10.1016\/j.thromres.2022.06.015.","journal-title":"Thromb Res"},{"key":"1819_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20406207221085202","volume":"13","author":"DP Hart","year":"2022","unstructured":"Hart DP, Matino D, Astermark J, Dolan G, d\u2019Oiron R, Hermans C, et al. International consensus recommendations on the management of people with haemophilia B. Ther Adv Hematol. 2022;13:1\u201322. https:\/\/doi.org\/10.1177\/20406207221085202.","journal-title":"Ther Adv Hematol"},{"key":"1819_CR22","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/hae.14357","volume":"27","author":"J Astermark","year":"2021","unstructured":"Astermark J, Holstein K, Abajas YL, Kearney S, Croteau SE, Liesner R, et al. The B-Natural study: the outcome of immune tolerance induction therapy in patients with severe haemophilia B. Haemophilia. 2021;27:802\u201313. https:\/\/doi.org\/10.1111\/hae.14357.","journal-title":"Haemophilia"},{"key":"1819_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/hae.14665","volume":"29","author":"X Dou","year":"2022","unstructured":"Dou X, Zhang W, Poon MC, Zhang X, Wu R, Feng X, et al. Factor IX inhibitors in haemophilia B: a report of National Haemophilia Registry in China. Haemophilia. 2022;29:123\u201334. https:\/\/doi.org\/10.1111\/hae.14665.","journal-title":"Haemophilia"},{"key":"1819_CR24","doi-asserted-by":"publisher","first-page":"CD010810","DOI":"10.1002\/14651858.CD010810.pub4","volume":"8","author":"L Jiang","year":"2020","unstructured":"Jiang L, Liu Y, Zhang L, Santoro C, Rodriguez A. Rituximab for treating inhibitors in people with inherited severe hemophilia. Cochrane Database Syst Rev. 2020;8:CD010810. https:\/\/doi.org\/10.1002\/14651858.CD010810.pub4.","journal-title":"Cochrane Database Syst Rev"},{"key":"1819_CR25","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1111\/hae.14471","volume":"28","author":"Z Li","year":"2022","unstructured":"Li Z, Liu G, Yao W, Chen Z, Li G, Cheng X, et al. Nephrotic syndrome in two haemophilia B children with inhibitor under low-dose immune tolerance induction combined with rituximab-based immunosuppressant protocol. Haemophilia. 2022;28:e42\u20135. https:\/\/doi.org\/10.1111\/hae.14471.","journal-title":"Haemophilia"},{"key":"1819_CR26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/hae.14577","volume":"28","author":"Z Li","year":"2022","unstructured":"Li Z, Liu G, Yao W, Chen Z, Li G, Cheng X, et al. Eradication of FIX inhibitor in haemophilia B children using low-dose immune tolerance induction with Rituximab-based immunosuppressive agent(s) in China. Haemophilia. 2022;28:625\u201332. https:\/\/doi.org\/10.1111\/hae.14577.","journal-title":"Haemophilia"},{"key":"1819_CR27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/mbc.0000000000000829","volume":"30","author":"JC Roberts","year":"2019","unstructured":"Roberts JC, Jesudas R, Tarantino MD. Development of an inhibitor in a child with severe hemophilia B: treatment with immunosuppression and an extended desensitization protocol. Blood Coag Fibrinolysis. 2019;30:291\u201394. https:\/\/doi.org\/10.1097\/mbc.0000000000000829.","journal-title":"Blood Coag Fibrinolysis"},{"key":"1819_CR28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1046\/j.1365-2516.2003.00772.x","volume":"9","author":"M Shibata","year":"2003","unstructured":"Shibata M, Shima M, Misu H, Okimoto Y, Giddings JC, Yoshioka A. Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates. Haemophilia. 2003;9:269\u201371. https:\/\/doi.org\/10.1046\/j.1365-2516.2003.00772.x.","journal-title":"Haemophilia"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-024-01819-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-024-01819-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-024-01819-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T12:07:48Z","timestamp":1732795668000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-024-01819-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1819"],"URL":"https:\/\/doi.org\/10.1186\/s13052-024-01819-2","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"11 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The infant\u2019s parents provided written consent for the publication of this case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"253"}}